CoChat
Sign Up
Cited by 16Monoclonal and Polyclonal Antibodies ResearchRadiopharmaceutical Chemistry and ApplicationsNanoplatforms for cancer theranostics

A promising cancer diagnosis and treatment strategy: Targeted cancer therapy and imaging based on antibody fragment

Open access
Zhao, Xuhong, Ning, Qian, Mo, Zhongcheng, Tang, Shengsong·2019·Artificial Cells, Nanomedicine, and Biotechnology
DOI 10.1080/21691401.2019.1657875
Open this paper in CoChat — free account

Abstract

With the arrival of the precision medicine and personalized treatment era, targeted therapy that improves efficacy and reduces side effects has become the mainstream approach of cancer treatment. Antibody fragments that further enhance penetration and retain the most critical antigen-specific binding functions are considered the focus of research targeting cancer imaging and therapy. Thanks to the superior penetration and rapid blood clearance of antibody fragments, antibody fragment-based imaging agents enable efficient and sensitive imaging of tumour sites. In tumour-targeted therapy, antibody fragments can directly inhibit tumour proliferation and growth, serve as an ideal carrier for delivery of anti-tumour drugs, or manipulate the immune system to eliminate tumour cells. In this review, the excellent physicochemical properties and the basic structure of antibody fragments are expressly depicted depicted, the progress of antibody fragments in cancer therapy and imaging are thoroughly summarized, and the future development of antibody fragments is predicted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21691401.2019.1657875

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Antibody fragments have tunable pharmacokinetic properties and the unique ability to detect biomarkers with high affinity and specificity in vitro and in vivo, making them excellent agents for tumor imaging.

    “Their tunable pharmacokinetic properties together with the unique ability to detect with high-affinity and specificity biomarkers in vitro and in vivo, making them excellent agents for tumor imaging [184,185].”

    From Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments (2020) · cites this paper as [184]

    The Introduction describes antibody fragments’ antigen-specific binding, short half-life and strong permeability, and says these properties make them suitable for tumour imaging. It does not establish the claimed high-affinity biomarker detection both in vitro and in vivo; it also notes that fragment affinity can be reduced relative to monoclonal antibodies. The cited copy provides no page numbers for these Introduction passages. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • In recent years, antibody fragments have achieved encouraging successes as theranostic agents contributing to the development of new personalized and more effective medicine.

    “In recent years, antibody fragments have also achieved encouraging successes as theranostic agents contributing to the development of new personalized and more effective medicine.”

    From Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments (2020) · cites this paper as [184]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 104

  1. Gao P, Mei C, He L, et al. Designing multifunctional cancer-targeted nanosystem for magnetic resonance molecular imaging-guided theranostics of lung cancer. Drug Deliv. 2018;25:1811–1825.
  2. Kovacs N, Szigeti K, Hegedus N, et al. Multimodal PET/MRI imaging results enable monitoring the side effects of radiation therapy. Contrast Media Mol Imaging. 2018;2018:5906471.
  3. Zhou Y, Zhen M, Guan M, et al. Amino acid modified [70] fullerene derivatives with high radical scavenging activity as promising bodyguards for chemotherapy protection. Sci Rep. 2018;8:16573.
  4. Movahedi MM, Mehdizadeh A, Koosha F, et al. Investigating the photo-thermo-radiosensitization effects of folate-conjugated gold nanorods on KB nasopharyngeal carcinoma cells. Photodiagnosis Photodyn Ther. 2018;24:324–331.
  5. Roskoski R. Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2018;139:395–411.
  6. Wang X, Ouyang X, Chen J, et al. Nanoparticulate photosensitizer decorated with hyaluronic acid for photodynamic/photothermal cancer targeting therapy. Nanomedicine (Lond). 2018;14:151–167.
  7. Warda W, Larosa F, Neto Da Rocha M, et al. CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells. Cancer Res. 2018;79:663–675.
  8. Xu L, Wan C, Du J, et al. Synthesis, characterization, and in vitro evaluation of targeted gold nanoshelled poly(d,l-lactide-co-glycolide) nanoparticles carrying anti p53 antibody as a theranostic agent for ultrasound contrast imaging and photothermal therapy. J Biomater Sci Polym Ed. 2017;28:415–430.
  9. Herbst RS, Redman MW, Kim ES, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018;19:101–114.
  10. Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722–730.
  11. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–628.
  12. Khoshtinat Nikkhoi S, Rahbarizadeh F, Ahmadvand D, et al. Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: in vitro proof-of-concept. Eur J Pharm Sci. 2018;122:42–50.
  13. He XX, Du S, Gao SQ, et al. Humanization of fibroblast growth factor 1 single-chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells. J Cell Mol Med. 2018;22:3259–3263.
  14. Shi S, Hong H, Orbay H, et al. ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. 2015;42:1295–1303.
  15. Zhang M, Kobayashi N, Zettlitz KA, et al. Near-infrared dye-labeled anti-prostate stem cell antigen minibody enables real-time fluorescence imaging and targeted surgery in translational mouse models. Clin Cancer Res. 2019;25:188–200.
  16. Leoh LS, Kim YK, Candelaria PV, et al. Efficacy and mechanism of antitumor activity of an antibody targeting transferrin receptor 1 in mouse models of human multiple myeloma. JI. 2018;200:3485–3494.
  17. Xin L, Cao J-Q, Liu C, et al. Evaluation of rMETase-loaded stealth PLGA/liposomes modified with anti-CAGE scFV for treatment of gastric carcinoma. J Biomed Nanotechnol. 2015;11:1153–1161.
  18. Min HS, Kim HJ, Ahn J, et al. Tuned density of anti-tissue factor antibody fragment onto siRNA-loaded polyion complex micelles for optimizing targetability into pancreatic cancer cells. Biomacromolecules. 2018;19:2320–2329.
  19. Xing J, Lin L, Li J, et al. BiHC, a T-cell-engaging bispecific recombinant antibody, has potent cytotoxic activity against Her2 tumor cells. Transl Oncol. 2017;10:780–785.
  20. Zhang Y, Guo J, Zhang XL, et al. Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells. Int J Pharm. 2015;496:1026–1033.
  21. Razzaqi M, Rasaee MJ, Paknejad M. A critical challenge in the development of antibody: selecting the appropriate fragment of the target protein as an antigen based on various epitopes or similar structure. Mol Immunol. 2019;111:128–135.
  22. Benschop RJ, Chow CK, Tian Y, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019;11:1175.
  23. Zettlitz KA, Tavare R, Tsai WK, et al. 18)F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice. Eur J Nucl Med Mol Imaging. 2019;46:489–500.
  24. Wingler LM, McMahon C, Staus DP, et al. Distinctive activation mechanism for angiotensin receptor revealed by a synthetic nanobody. Cell. 2019;176:479–490.e12.
  25. Li C, Wang Y, Liu T, et al. An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion. Antiviral Res. 2019;162:118–129.
  26. Xavier S, Gopi Mohan C, Nair S, et al. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation. Int J Biol Macromol. 2019;124:17–24.
  27. Lv J, Zhao R, Wu D, et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019;12:6380000.
  28. Groof Twm D, Mashayekhi V, Fan TS, et al. Nanobody-targeted photodynamic therapy selectively kills viral GPCR-expressing glioblastoma cells. Mol Pharm. 2019;16:3145–3156.
  29. Li T, Vandesquille M, Koukouli F, et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control Release. 2016;243:1–10.
  30. Vandesquille M, Li T, Po C, et al. Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease. MAbs. 2017;9:1016–1027.
  31. Volz J, Mammadova-Bach E, Gil-Pulido J, et al. Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice. Blood. 2019;133:2696–2706.
  32. Liu W, Zhao W, Bai X, et al. High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates. Eur J Pharm Sci. 2019;134:81–92.
  33. Beha N, Harder M, Ring S, et al. IL-15-based trifunctional antibody-fusion proteins with costimulatory TNF-superfamily ligands in the single-chain format for cancer immunotherapy. Mol Cancer Ther. 2019;18:1278.
  34. Lu L, Liu N, Fan K, et al. A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions. Mol Immunol. 2019;109:149–156.
  35. Iizuka A, Nonomura C, Ashizawa T, et al. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv antibody targets human breast cancer. Clin Cancer Res. 2019;25:2925–2934.
  36. Kapelski S, Cleiren E, Attar RM, et al. Influence of the bispecific antibody IgG subclass on T cell redirection. MAbs. 2019;26:1–13.
  37. Haylock AK, Spiegelberg D, Mortensen AC, et al. Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma. Int J Oncol. 2016;48:461–470.
  38. El-Sayed A, Bernhard W, Barreto K, et al. Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts. Theranostics. 2018;8:4856–4869.
  39. Alric C, Herve-Aubert K, Aubrey N, et al. Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes. J Nanobiotechnol. 2018;16:18.
  40. Ueda M, Hisada H, Temma T, et al. Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression. Mol Imaging Biol. 2015;17:102–110.
  41. Tsai WK, Zettlitz KA, Tavare R, et al. Dual-modality immunoPET/fluorescence imaging of prostate cancer with an anti-PSCA Cys-minibody. Theranostics. 2018;8:5903–5914.
  42. Boogerd LSF, Boonstra MC, Prevoo H, et al. Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: preclinical validation. Surg Oncol. 2019;28:1–8.
  43. Knowles SM, Tavare R, Zettlitz KA, et al. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clin Cancer Res. 2014;20:6367–6378.
  44. Zhang M, Kobayashi N, Zettlitz KA, et al. Near-infrared dye-labeled anti-prostate stem cell antigen minibody enables real-time fluorescence imaging and targeted surgery in translational mouse models. Clin Cancer Res. 2019;25:188–200.
  45. Solomon VR, Gonzalez C, Alizadeh E, et al. Tc(CO)3(+) labeled domain I/II-specific anti-EGFR (scFv)2 antibody fragment for imaging EGFR expression. Eur J Med Chem. 2018;157:437–446.
  46. Vaidyanathan G, McDougald D, Choi J, et al. Preclinical evaluation of 18F-labeled Anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET. J Nucl Med. 2016;57:967–973.
  47. Gao Y, Hernandez C, Yuan HX, et al. Ultrasound molecular imaging of ovarian cancer with CA-125 targeted nanobubble contrast agents. Nanomedicine. 2017;13:2159–2168.
  48. Long NE, Sullivan BJ, Ding H, et al. Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging. J Biol Chem. 2018;293:9030–9040.
  49. Rios X, Compte M, Gomez-Vallejo V, et al. Immuno-PET imaging and pharmacokinetics of an anti-CEA scFv-based trimerbody and its monomeric counterpart in human gastric carcinoma-bearing mice. Mol Pharmaceutics. 2019;16:1025–1035.
  50. Zhang X, Liu C, Hu F, et al. PET imaging of VCAM-1 expression and monitoring therapy response in tumor with a (68)Ga-labeled single chain variable fragment. Mol Pharmaceutics. 2018;15:609–618.
  51. Zhou Z, McDougald D, Devoogdt N, et al. Labeling single domain antibody fragments with fluorine-18 using 2,3,5,6-tetrafluorophenyl 6-[(18)F]fluoronicotinate resulting in high tumor-to-kidney ratios. Mol Pharmaceutics. 2019;16:214–226.
  52. Uehara T, Yokoyama M, Suzuki H, et al. A Gallium-67/68-labeled antibody fragment for immuno-SPECT/PET shows low renal radioactivity without loss of tumor uptake. Clin Cancer Res. 2018;24:3309–3316.
  53. Chen F, Ma K, Madajewski B, et al. Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nat Commun. 2018;9:4141.
  54. Bauerschlag D, Meinhold-Heerlein I, Maass N, et al. Detection and specific elimination of EGFR(+) ovarian cancer cells using a near infrared photoimmunotheranostic approach. Pharm Res. 2017;34:696–703.
  55. Yuan X, Yang M, Chen X, et al. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. Cancer Immunol Immunother. 2017;66:367–378.
  56. Mazzocco C, Fracasso G, Germain-Genevois C, et al. In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe. Sci Rep. 2016;6:23314.
  57. Boonstra MC, Tolner B, Schaafsma BE, et al. Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors. Int J Cancer. 2015;137:1910–1920.
  58. Sonn GA, Behesnilian AS, Jiang ZK, et al. Fluorescent image-guided surgery with an anti-prostate stem cell antigen (PSCA) diabody enables targeted resection of mouse prostate cancer xenografts in real time. Clin Cancer Res. 2016;22:1403–1412.
  59. Luo H, Hernandez R, Hong H, et al. Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proc Natl Acad Sci USA. 2015;112:12806–12811.
  60. Guo Y, Wang XY, Chen YL, et al. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy. Acta Biomater. 2018;80:308–326.
  61. Luo H, England CG, Goel S, et al. ImmunoPET and near-infrared fluorescence imaging of pancreatic cancer with a dual-labeled bispecific antibody fragment. Mol Pharmaceutics. 2017;14:1646–1655.
  62. Hernot S, Unnikrishnan S, Du Z, et al. Nanobody-coupled microbubbles as novel molecular tracer. J Control Release. 2012;158:346–353.
  63. Fan X, Wang L, Guo Y, et al. Ultrasonic nanobubbles carrying anti-PSMA nanobody: construction and application in prostate cancer-targeted imaging. PLoS One. 2015;10:e0127419.
  64. Kanazaki K, Sano K, Makino A, et al. Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging. Nanomedicine. 2015;11:2051–2060.
  65. Lei G, Xu M, Xu Z, et al. A novel fully human agonistic single chain fragment variable antibody targeting death receptor 5 with potent antitumor activity in vitro and in vivo. Int J Mol Sci. 2017;18:2064.
  66. Rabenhold M, Steiniger F, Fahr A, et al. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously. J Control Release. 2015;201:56–67.
  67. Yang W, Hu Q, Xu Y, et al. Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Mater Sci Eng C Mater Biol Appl. 2018;89:328–335.
  68. Kim M, Pyo S, Kang CH, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS One. 2018;13:e0198347.
  69. Pearce AK, Fuchs AV, Fletcher NL, et al. Targeting nanomedicines to prostate cancer: evaluation of specificity of ligands to two different receptors in vivo. Pharm Res. 2016;33:2388–2399.
  70. Ji X, Shen Y, Sun H, et al. A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel. Tumor Biol. 2016;37:10085–10096.
  71. Lee D, Kim D, Choi YB, et al. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. MAbs. 2016;8:892–904.
  72. Ahn HM, Ryu J, Song JM, et al. Anti-cancer activity of novel TM4SF5-targeting antibodies through TM4SF5 neutralization and immune cell-mediated cytotoxicity. Theranostics. 2017;7:594–613.
  73. Lu Y, Wang Y, Zhang M, et al. HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth. Oncotarget. 2016;7:23594–23607.
  74. Sokolova E, Proshkina G, Kutova O, et al. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo. J Control Release. 2016;233:48–56.
  75. Amoury M, Kolberg K, Pham AT, et al. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. Cancer Lett. 2016;372:201–209.
  76. Lv X, Zhang J, Xu R, et al. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells. Appl Microbiol Biotechnol. 2016;100:6403–6413.
  77. Aubrey N, Allard-Vannier E, Martin C, et al. Site-specific conjugation of Auristatins onto engineered scFv using second generation maleimide to target HER2-positive breast cancer in vitro. Bioconjugate Chem. 2018;29:3516–3521.
  78. Tang J, Howard CB, Mahler SM, et al. Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands. Nanoscale. 2018;10:4258–4266.
  79. Hou SC, Chen HS, Lin HW, et al. High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries. Sci Rep. 2016;6:31878.
  80. Amoury M, Mladenov R, Nachreiner T, et al. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein. Int J Cancer. 2016;139:916–927.
  81. Su Y, Yu L, Liu N, et al. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Cancer Lett. 2013;338:282–291.
  82. Jiang K, Li J, Yin J, et al. Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy. Biomaterials. 2015;59:77–87.
  83. Kaplan G, Mazor R, Lee F, et al. Improving the in vivo efficacy of an Anti-Tac (CD25) immunotoxin by pseudomonas exotoxin A domain II engineering. Mol Cancer Ther. 2018;17:1486–1493.
  84. Geddie ML, Kohli N, Kirpotin DB, et al. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs. 2017;9:58–67.
  85. Li Y, Chen Y, Li J, et al. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. Cancer Sci. 2017;108:1493–1503.
  86. Herve-Aubert K, Allard-Vannier E, Joubert N, et al. Impact of site-specific conjugation of ScFv to multifunctional nanomedicines using second generation maleimide. Bioconjugate Chem. 2018;29:1553–1559.
  87. Niwa T, Kasuya Y, Suzuki Y, et al. Novel immunoliposome technology for enhancing the activity of the agonistic antibody against the tumor necrosis factor receptor superfamily. Mol Pharmaceutics. 2018;15:3729–3740.
  88. Sarisozen C, Dhokai S, Tsikudo EG, et al. Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models. Eur J Pharm Biopharm. 2016;108:54–67.
  89. Chang, T M S.ARTIFICIAL CELL evolves into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology. Artificial Cells, Nanomedicine, and Biotechnology. 2019;47(1):997–1013. doi:10.1080/21691401.2019.1577885. · DOI
  90. Li T, Amari T, Semba K, et al. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells. Nanomedicine. 2017;13:1219–1227.
  91. Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9:5150.
  92. Libutti SK, Tamarkin L, Nilubol N. Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure. Oncotarget. 2018;9:35723–35725.
  93. Miyazaki T, Ikeda K, Sato W, et al. Extracellular vesicle-mediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression. Oncogenesis. 2018;7:7.
  94. Riley, R S, June, C H, Langer, R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–196. doi:10.1038/s41573-018-0006-z. · DOI
  95. Jiang H, Shi Z, Wang P, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111:409–418.
  96. de Bruin RCG, Veluchamy JP, Lougheed SM, et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vgamma9Vdelta2-T cells. Oncoimmunology. 2018;7:e1375641.
  97. Zhang C, Oberoi P, Oelsner S, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533.
  98. Harwood SL, Alvarez-Cienfuegos A, Nunez-Prado N, et al. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology. 2018;7:e1377874.
  99. Chan WK, Kang S, Youssef Y, et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunol Res. 2018;6:776–787.
  100. Satta A, Mezzanzanica D, Caroli F, et al. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs. 2018;10:1084–1097.
  101. Ahmed M, Cheng M, Cheung IY, et al. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. Oncoimmunology. 2015;4:e989776.
  102. Krenciute G, Krebs S, Torres D, et al. Characterization and functional analysis of scFv-based chimeric antigen receptors to redirect T cells to IL13Ralpha2-positive glioma. Mol Ther. 2016;24:354–363.
  103. Golubovskaya V, Berahovich R, Zhou H, et al. CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers (Basel). 2017;9:139.
  104. Romanski A, Uherek C, Bug G, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20:1287–1294.

Cited by

Sorted by citations

Authors
Zhao, X., Ning, Q., Mo, Z., & Tang, S.
Affiliations
  • Hunan University of Medicine (CN)
  • University of South China (CN)
Corresponding author
Tang, Shengsong
ORCID
Venue
Artificial Cells, Nanomedicine, and Biotechnology
Publisher
Informa UK Limited
Published
2019-08-30
Volume
47
Issue
1
Pages
3621-3630
ISSN
  • 2169-1401 (ISSN-L)
  • 2169-141X
DOI
10.1080/21691401.2019.1657875
OpenAlex
W2970343612
Cited by
16
References
3
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 2
FWCI
0.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Artificial Cells Nanomedicine and Biotechnology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (30270684)
  • Hunan Provincial Science and Technology Plan Key Projects of China (2017SK2183)
  • Science and Technology Plan Key Projects of Hunan Province (10A087)
  • the Hunan Provincial University Innovation Platform Open Fund Project (09K072, 12K120, 15K111)
  • Hunan Provincial Natural Science Foundation of China (2019JJ50416)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
antibody fragments, targeted cancer therapy, tumor imaging, tumour-targeted drug delivery, cancer immunotherapy, tumor penetration, precision medicine
MeSH terms
Diagnostic Imaging, Humans, Immunoglobulin Fragments, Neoplasms, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review